MedTrace Logo

IMpact of hyPeRkalaemia on thErapy With Renin angiotenSin aldoSterone System Inhibitors

NCT04510792 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-12-23

No results posted yet for this study

Summary

There are limited data regarding the burden of hyperkalaemia in patients attending emergency departments (ED) or who are hospitalised (excluding those already receiving dialysis). Renin-angiotensin-aldosterone system inhibitors (RAASi) are of prognostic benefit in patients with heart failure with reduced ejection fraction (HFrEF) and post myocardial infarction (MI) left ventricular systolic dysfunction (LVSD) and as such should be continued wherever possible for these indications. These drugs may contribute to elevation in serum potassium and hyperkalaemia may lead to a reduction in dose or complete withdrawal of RAASi. Yet it remains unknown how common this happens in standard clinical practice. Inappropriate discontinuation of RAASi in such patients may lead to adverse clinical outcomes. If patients have hyperkalaemia that limits the use of RAASi, they may be candidates for new potassium binders that could facilitate their continued use.

Conditions

  • Hyperkalemia

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Vifor Pharma

    collaborator INDUSTRY

  • Portsmouth Hospitals NHS Trust

    lead OTHER_GOV

Principal Investigators

  • Paul R Kalra, Professor · Portsmouth Hospitals University NHS Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2021-07-12
Completion
2021-07-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04510792 on ClinicalTrials.gov